ACTG begins study of pramipexole versus escitalopram for depression and mild neurocognitive disorder in people with HIV

financialpost.com

ACTG launched a study to evaluate pramipexole versus escitalopram for depression and mild neurocognitive disorder in people with HIV. The A5402 trial will assess the safety and efficacy of these two treatments in 186 participants on antiretroviral therapy. Depression and mild neurocognitive disorder affect a significant portion of people living with HIV, impacting their health and quality of life.


With a significance score of 4.2, this news ranks in the top 4.6% of today's 32994 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: